Delving into the Latest Updates on Beijing Diwei Huayu Bio-Technology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Fusion protein

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Fusion protein	1

Main purpose: To evaluate the safety and tolerability of multiple administrations of lyophilized recombinant anti-tumor fusion protein for injection in humans, and to provide a safe dosage range for the formulation of the dosing regimen for Phase II clinical trials of this product. Secondary purpose: To preliminarily observe the anti-tumor efficacy of lyophilized recombinant anti-tumor fusion protein for injection.

Start Date03 Apr 2009

Sponsor / Collaborator

Beijing Diwei Huayu Bio-Technology Co., Ltd.

100 Clinical Results associated with Beijing Diwei Huayu Bio-Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Diwei Huayu Bio-Technology Co., Ltd.

Login to view more data

100 Deals associated with Beijing Diwei Huayu Bio-Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Diwei Huayu Bio-Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 16 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Other

Login to view more data